Blue Cross and Blue Shield of Illinois (BCBSIL) and Illinois Cancer Specialists (ICS) have announced the very first oncology intensive medical home (IMH) pilot program in Illinois. Read More »
Amgen and UCB have announced the results of the Phase 3 trial for romosozumab. Read More »
In the wake of recent scandals involving drug manufacturers such as Valeant, renewed attention has been drawn to the skyrocketing cost of prescription drugs and the attendant problem of rising health insurance costs across the U.S. Read More »
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Iomab-B, a radioimmunotherapeutic developed by Actinium Pharmaceuticals that is designed to aid patients with reverted and stubborn Acute Myeloid Leukemia (AML) so they can receive a Hematopoietic Stem Cell Transplant (HSCT). Read More »
Oasmia Pharmaceuticals, which develops innovative drugs within human and veterinary oncology, has announced that the first patient to take part in the Phase 1 clinical trial for Docecal, the company’s groundbreaking cancer treatment, has been enrolled. Read More »
Actinium Pharmaceuticals has announced that it has named Jennifer Liberi Director of Clinical Operations. Read More »
Recent research conducted by ResearchersAgainstAlzheimer’s (RA2), an UsAgainstAlzheimer’s (UsA2) network, reports 17 new drugs aimed at treating Alzheimer’s will be developed in the next five years. Read More »
Eisai Co. Ltd. and Ajinomoto Co. Inc. have announced the establishment of EA Pharma Co. Ltd., based on the integration agreement signed by both companies on October 15 of last year. Read More »
Eisai Co. Ltd. has announced that Eisai Inc., the company’s subsidiary located in the United States, has entered into a shared purchase agreement that will transfer all of Eisai Inc.’s shares of AkaRx Inc. to PBM Capital Group LLC. Read More »
Pfizer and Bristol-Myers Squibb have released the 17 abstracts that the two companies will present at the American College of Cardiology’s 65th Annual Scientific Session (ACC.16) in Chicago on April 2-4. Read More »
Sanofi and Regeneron Pharmaceuticals will be presenting new joint Phase 3 data from the clinical trial for the Praluent (alirocumab) Injection at the American College of Cardiology’s 65th Annual Scientific Session & Expo (ACC.16) in Chicago on April 2-4. Read More »
Teva Pharmaceutical Industries has announced that the U.S. Food and Drug Administration (FDA) has approved its interleukin 5 antagonist monoclonal antibody (lgG4 kappa), CINQAIR (reslizumab) Injection. Read More »
UnitedHealthcare celebrated the opening of its new office in Davenport, Iowa last week and the expansion of its headquarters located in West Des Moines. Read More »
Walgreens has confirmed that it will be returning as the second annual Red Nose Day’s exclusive retail partner on May 26. Read More »
UnitedHealthcare Community Plan of Louisiana announced this week that it has awarded more than $3.4 million to 249 physician practices across the state as bonus payments for improving the quality of care for patients who are enrolled in UnitedHealthcare’s Medicaid plans. Read More »
The CVS Health Foundation has released new data from programs that were part of a collaborative effort with the National Association of Free & Charitable Clinics (NAFC) and the National Association of Community Health Centers (NACHC) as part of CVS Health’s multi-year, $5-million commitment to increase nationwide access to health care in communities. Read More »
The Japanese Ministry of Health, Labor and Welfare (MHLW) today approved AstraZeneca's Tagrisso (osimertinib, AZD9291). Read More »
CVS Health has announced that CVS Caremark, its pharmacy benefits manager, has been awarded the Mail Service Pharmacy accreditation by the URAC, a health care accreditation organization located in Washington, D.C. Read More »
Alkermes plc has released data from its schizophrenia portfolio that will be featured at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference that will be held from April 2-6 in Florence Italy. Read More »
Sarepta Therapeutics has announced that its New Drug application (NDA) for eteplirsen will be reviewed by the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System (PCNS) Drug Advisory Committee on April 25. Read More »
Alerts Sign-up
